NASDAQ:EOLS

Evolus Competitors

$13.58
-0.33 (-2.37 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.28
Now: $13.58
$14.43
50-Day Range
$7.16
MA: $12.57
$16.51
52-Week Range
$2.85
Now: $13.58
$17.38
Volume420,375 shs
Average Volume1.55 million shs
Market Capitalization$593.89 million
P/E RatioN/A
Dividend YieldN/A
Beta2.69

Competitors

Evolus (NASDAQ:EOLS) Vs. XNCR, AMRN, RCUS, PBH, IGMS, and RVNC

Should you be buying EOLS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Evolus, including Xencor (XNCR), Amarin (AMRN), Arcus Biosciences (RCUS), Prestige Consumer Healthcare (PBH), IGM Biosciences (IGMS), and Revance Therapeutics (RVNC).

Xencor (NASDAQ:XNCR) and Evolus (NASDAQ:EOLS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Institutional & Insider Ownership

21.7% of Evolus shares are held by institutional investors. 3.7% of Xencor shares are held by company insiders. Comparatively, 10.1% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Xencor and Evolus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Xencor-113.40%-13.56%-12.03%
Evolus-120.63%-121.11%-30.91%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Xencor and Evolus, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Xencor20702.56
Evolus14402.33

Xencor presently has a consensus price target of $47.1111, suggesting a potential upside of 16.41%. Evolus has a consensus price target of $13.8889, suggesting a potential upside of 2.27%. Given Xencor's stronger consensus rating and higher probable upside, research analysts plainly believe Xencor is more favorable than Evolus.

Earnings & Valuation

This table compares Xencor and Evolus' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xencor$156.70 million14.97$26.88 million$0.4687.98
Evolus$34.92 million17.01$-90,030,000.00($3.19)-4.26

Xencor has higher revenue and earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Xencor has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Evolus has a beta of 2.69, indicating that its stock price is 169% more volatile than the S&P 500.

Summary

Xencor beats Evolus on 9 of the 14 factors compared between the two stocks.

Amarin (NASDAQ:AMRN) and Evolus (NASDAQ:EOLS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Institutional & Insider Ownership

37.8% of Amarin shares are held by institutional investors. Comparatively, 21.7% of Evolus shares are held by institutional investors. 2.8% of Amarin shares are held by company insiders. Comparatively, 10.1% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Amarin and Evolus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amarin-2.69%-2.70%-1.72%
Evolus-120.63%-121.11%-30.91%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Amarin and Evolus, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amarin03802.73
Evolus14402.33

Amarin presently has a consensus price target of $11.1818, suggesting a potential upside of 88.56%. Evolus has a consensus price target of $13.8889, suggesting a potential upside of 2.27%. Given Amarin's stronger consensus rating and higher probable upside, research analysts plainly believe Amarin is more favorable than Evolus.

Earnings & Valuation

This table compares Amarin and Evolus' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amarin$429.76 million5.43$-22,650,000.00($0.07)-84.71
Evolus$34.92 million17.01$-90,030,000.00($3.19)-4.26

Amarin has higher revenue and earnings than Evolus. Amarin is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Amarin has a beta of 2.58, indicating that its stock price is 158% more volatile than the S&P 500. Comparatively, Evolus has a beta of 2.69, indicating that its stock price is 169% more volatile than the S&P 500.

Summary

Amarin beats Evolus on 10 of the 14 factors compared between the two stocks.

Arcus Biosciences (NYSE:RCUS) and Evolus (NASDAQ:EOLS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Arcus Biosciences and Evolus, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arcus Biosciences00903.00
Evolus14402.33

Arcus Biosciences presently has a consensus price target of $49.9091, suggesting a potential upside of 59.45%. Evolus has a consensus price target of $13.8889, suggesting a potential upside of 2.27%. Given Arcus Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Arcus Biosciences is more favorable than Evolus.

Institutional & Insider Ownership

60.6% of Arcus Biosciences shares are held by institutional investors. Comparatively, 21.7% of Evolus shares are held by institutional investors. 19.7% of Arcus Biosciences shares are held by company insiders. Comparatively, 10.1% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Arcus Biosciences has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Evolus has a beta of 2.69, indicating that its stock price is 169% more volatile than the S&P 500.

Profitability

This table compares Arcus Biosciences and Evolus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arcus Biosciences-112.63%-27.43%-20.96%
Evolus-120.63%-121.11%-30.91%

Earnings & Valuation

This table compares Arcus Biosciences and Evolus' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcus Biosciences$15 million147.89$-84,710,000.00($1.93)-16.22
Evolus$34.92 million17.01$-90,030,000.00($3.19)-4.26

Arcus Biosciences has higher earnings, but lower revenue than Evolus. Arcus Biosciences is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.

Summary

Arcus Biosciences beats Evolus on 11 of the 14 factors compared between the two stocks.

Evolus (NASDAQ:EOLS) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Evolus and Prestige Consumer Healthcare, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evolus14402.33
Prestige Consumer Healthcare04302.43

Evolus presently has a consensus target price of $13.8889, suggesting a potential upside of 2.27%. Prestige Consumer Healthcare has a consensus target price of $87.60, suggesting a potential upside of 100.23%. Given Prestige Consumer Healthcare's stronger consensus rating and higher probable upside, analysts clearly believe Prestige Consumer Healthcare is more favorable than Evolus.

Institutional and Insider Ownership

21.7% of Evolus shares are owned by institutional investors. 10.1% of Evolus shares are owned by company insiders. Comparatively, 1.2% of Prestige Consumer Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Evolus has a beta of 2.69, indicating that its share price is 169% more volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Profitability

This table compares Evolus and Prestige Consumer Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evolus-120.63%-121.11%-30.91%
Prestige Consumer Healthcare17.03%13.76%4.80%

Valuation & Earnings

This table compares Evolus and Prestige Consumer Healthcare's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evolus$34.92 million17.01$-90,030,000.00($3.19)-4.26
Prestige Consumer Healthcare$963.01 million2.27$142.28 million$2.9614.78

Prestige Consumer Healthcare has higher revenue and earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Summary

Prestige Consumer Healthcare beats Evolus on 9 of the 14 factors compared between the two stocks.

Evolus (NASDAQ:EOLS) and IGM Biosciences (NASDAQ:IGMS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Evolus and IGM Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evolus14402.33
IGM Biosciences01602.86

Evolus presently has a consensus target price of $13.8889, suggesting a potential upside of 2.27%. IGM Biosciences has a consensus target price of $98.8750, suggesting a potential upside of 44.36%. Given IGM Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe IGM Biosciences is more favorable than Evolus.

Institutional and Insider Ownership

21.7% of Evolus shares are owned by institutional investors. Comparatively, 47.6% of IGM Biosciences shares are owned by institutional investors. 10.1% of Evolus shares are owned by company insiders. Comparatively, 79.3% of IGM Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Evolus has a beta of 2.69, indicating that its share price is 169% more volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of -1.12, indicating that its share price is 212% less volatile than the S&P 500.

Profitability

This table compares Evolus and IGM Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evolus-120.63%-121.11%-30.91%
IGM BiosciencesN/A-33.30%-30.28%

Valuation & Earnings

This table compares Evolus and IGM Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evolus$34.92 million17.01$-90,030,000.00($3.19)-4.26
IGM BiosciencesN/AN/A$-43,130,000.00($4.80)-14.27

IGM Biosciences has lower revenue, but higher earnings than Evolus. IGM Biosciences is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.

Summary

IGM Biosciences beats Evolus on 9 of the 13 factors compared between the two stocks.

Evolus (NASDAQ:EOLS) and Revance Therapeutics (NASDAQ:RVNC) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Evolus and Revance Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evolus14402.33
Revance Therapeutics00503.00

Evolus presently has a consensus target price of $13.8889, suggesting a potential upside of 2.27%. Revance Therapeutics has a consensus target price of $36.40, suggesting a potential upside of 29.40%. Given Revance Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Revance Therapeutics is more favorable than Evolus.

Institutional and Insider Ownership

21.7% of Evolus shares are owned by institutional investors. Comparatively, 74.4% of Revance Therapeutics shares are owned by institutional investors. 10.1% of Evolus shares are owned by company insiders. Comparatively, 4.8% of Revance Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Evolus has a beta of 2.69, indicating that its share price is 169% more volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500.

Profitability

This table compares Evolus and Revance Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evolus-120.63%-121.11%-30.91%
Revance Therapeutics-5,818.87%-85.72%-44.85%

Valuation & Earnings

This table compares Evolus and Revance Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evolus$34.92 million17.01$-90,030,000.00($3.19)-4.26
Revance Therapeutics$410,000.004,897.57$-159,430,000.00($3.67)-7.66

Evolus has higher revenue and earnings than Revance Therapeutics. Revance Therapeutics is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.


Evolus Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Xencor logo
XNCR
Xencor
1.2$40.47-2.9%$2.35 billion$156.70 million-28.91News Coverage
Gap Down
Amarin logo
AMRN
Amarin
1.6$5.93-1.2%$2.33 billion$429.76 million-118.58
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$31.30-1.3%$2.22 billion$15 million-16.39
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.75-0.5%$2.18 billion$963.01 million13.59Analyst Upgrade
News Coverage
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$68.49-16.4%$2.10 billionN/A-29.14Insider Selling
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13-1.4%$2.01 billion$410,000.00-6.12
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.09-1.3%$1.99 billion$23.90 million-16.20Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.99-2.1%$1.98 billionN/A-19.70
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.43-3.8%$1.95 billion$103.54 million-19.12Gap Down
MORF
Morphic
1.1$59.35-3.0%$1.93 billion$16.98 million-38.04Insider Selling
Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$28.57-0.8%$1.89 billionN/A-17.53
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.58-0.1%$1.88 billion$34.51 million-17.59News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.4%$1.88 billionN/A-10.57
MacroGenics logo
MGNX
MacroGenics
1.2$31.16-1.3%$1.87 billion$64.19 million-9.96News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.96-2.7%$1.79 billion$1.63 billion14.54News Coverage
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.94-0.1%$1.77 billion$14.87 million-14.16News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$48.93-21.0%$1.72 billionN/A0.00Insider Buying
Gap Down
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.16-0.1%$1.72 billion$26.87 million-12.65
FibroGen logo
FGEN
FibroGen
1.8$18.57-1.3%$1.70 billion$256.58 million-7.11Analyst Downgrade
Unusual Options Activity
Analyst Revision
News Coverage
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$41.57-1.3%$1.66 billionN/A-173.21
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.99-7.6%$1.65 billion$2.34 million-10.17Gap Down
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.15-1.2%$1.65 billionN/A-6.46Insider Selling
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$35.26-6.0%$1.64 billionN/A0.00Insider Selling
News Coverage
Gap Down
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.19-1.5%$1.64 billion$428.41 million14.77
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.80-1.3%$1.63 billion$320,000.00-8.71News Coverage
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.32-0.2%$1.61 billionN/A0.00
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.61-1.4%$1.55 billion$175.34 million-15.06
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.8$37.41-13.5%$1.54 billionN/A0.00Insider Selling
Gap Down
Generation Bio logo
GBIO
Generation Bio
1.8$27.20-5.3%$1.53 billionN/A0.00Insider Selling
News Coverage
Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$27.28-0.3%$1.53 billionN/A0.00Lockup Expiration
uniQure logo
QURE
uniQure
1.7$33.74-5.2%$1.52 billion$7.28 million-8.95Gap Down
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.60-4.0%$1.52 billion$145.97 million-6.72News Coverage
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.56-3.8%$1.51 billion$82.27 million-18.44Unusual Options Activity
News Coverage
Gap Down
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$28.96-0.4%$1.50 billion$4.23 million-21.45
ATBPD
Antibe Therapeutics
0.1$3.88-0.5%$1.50 billion$7.51 million-6.46Gap Down
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$28.31-0.7%$1.50 billion$392.76 million11.75Analyst Revision
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$33.30-2.3%$1.49 billionN/A0.00Insider Selling
News Coverage
Gap Down
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$29.19-5.9%$1.46 billion$19.89 million-13.77Unusual Options Activity
News Coverage
Gap Up
Zymeworks logo
ZYME
Zymeworks
1.8$31.00-1.5%$1.43 billion$29.54 million-8.22News Coverage
Endo International logo
ENDP
Endo International
1.3$6.20-1.0%$1.43 billion$2.91 billion-9.12Analyst Report
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.80-1.5%$1.42 billion$6.20 million-14.39
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$60.16-4.3%$1.40 billionN/A0.00Gap Down
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$20.95-3.9%$1.37 billion$73.41 million-4.43Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$26.62-3.5%$1.33 billionN/A-2.88Gap Down
OLMA
Olema Pharmaceuticals
1.6$32.84-0.4%$1.32 billionN/A0.00
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$35.80-3.8%$1.31 billionN/A0.00Gap Down
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$34.35-2.6%$1.26 billionN/A-19.08News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.51-1.3%$1.26 billion$4.23 million-9.22Gap Down
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$33.90-7.8%$1.21 billion$57.05 million0.00Gap Down
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.